Edwards Lifesciences (EW) Long-Term Debt Issuances (2009 - 2021)

Edwards Lifesciences' Long-Term Debt Issuances history runs 11 years deep, the most recent figure standing at -$8.8 million for Q3 2021.

• On a quarterly basis, Long-Term Debt Issuances fell 617.65% year-over-year to -$8.8 million in Q3 2021; TTM through Jun 2022 was -$8.8 million, a 144.9% decrease from a year earlier, with the FY2021 full-year figure at $5.2 million, down 67.9% from the prior year.
• Long-Term Debt Issuances eased to -$8.8 million in Q3 2021 per EW's latest filing, from $9.5 million in the prior quarter.
• Across five years, Long-Term Debt Issuances topped out at $608.0 million in Q2 2017 and bottomed at -$8.8 million in Q3 2021.
• The 5-year median for Long-Term Debt Issuances is $4.5 million (2021), against an average of $86.4 million.
• Across the five-year window, Long-Term Debt Issuances jumped 9706.45% in 2017 and slumped 617.65% in 2021, its largest moves.
• Year by year, Long-Term Debt Issuances stood at $5.4 million in 2017, then slumped by 70.37% to $1.6 million in 2018, then surged by 331.25% to $6.9 million in 2019, then plunged by 43.48% to $3.9 million in 2020, then sank by 325.64% to -$8.8 million in 2021.
• Per Business Quant, the three latest EW Long-Term Debt Issuances figures stand at -$8.8 million (Q3 2021), $9.5 million (Q2 2021), and $4.5 million (Q1 2021).